Startup Deep Dive : MediBuddy — one acquisition did more than a Bachchan ad campaign

MediBuddy told the country its most trusted health consultant was Amitabh Bachchan. It spent ₹119.5 crore on that single ad campaign in FY22, nearly seven times what it had spent the year before, and its net loss still climbed to ₹259.3 crore that year, as per Entrackr’s report on the company’s financial filings.

Two years later, one acquisition — not one more advertisement — did what the marketing budget could not. Operating revenue more than doubled from ₹297.7 crore in FY23 to ₹645.4 crore in FY24, and by FY25 the company had narrowed its losses by 37% even as revenue crossed ₹724.6 crore (₹724.6 crore ≈ $75.5 million at $1 ≈ ₹96.0), Entrackr reported in December 2025.

Quick facts

What they do

MediBuddy is a digital healthcare platform that lets a person in India talk to a doctor, book a lab test, order medicines, or schedule a health checkup from one app, and it sells a version of the same bundle to employers who want to offer it as a workplace benefit. The consumer-facing product looks like most telehealth apps: video or phone consultations with doctors across specialities, home sample collection for diagnostics, and delivery of prescription medicines. The less visible but larger part of the business, built through the 2023 acquisition of vHealth by Aetna, is a business-to-business health benefits programme that employers buy on behalf of staff — doctor access, preventive checks, and a managed network of hospitals and diagnostic centres, sold as a subscription per employee rather than a one-off transaction. By its own account, MediBuddy’s network runs to 90,000 doctors, 7,000 hospitals and 3,000 diagnostic centres, with tie-ups across more than 2,500 pharmacies, according to Inc42’s coverage of the 2022 DocsApp merger completion.

The origin

The founding company was DocsApp, started in 2015 by Satish Kannan and Enbasekar Dinadayalane, engineering classmates at IIT Madras, according to Business2Business’s account of the company’s history. Their insight was narrow and specific: a large share of common health complaints in India did not need a physical visit to a doctor, they could be triaged and often resolved over a phone or video call, if patients trusted the privacy of the channel and doctors trusted the diagnosis they could make without touching the patient. DocsApp built its early business around exactly that transaction — a paid, on-demand consultation with a verified doctor, priced low enough to compete with an unpaid visit to a neighbourhood clinic.

MediBuddy existed separately as a broader digital-health brand offering lab bookings, consultations and medicine ordering. In June 2020, in the middle of the country’s first COVID-19 lockdowns, DocsApp announced it would combine with MediBuddy in a cash-and-stock deal, with the two brands initially expected to run independently under a shared parent, Phasorz Technologies, Business2Business and Inc42 reported. Telehealth demand during the pandemic gave the newly combined entity an unusually favourable moment to raise capital and scale consultations at once — a tailwind neither founder could have planned for when they started DocsApp five years earlier.

The struggle years

The merger did not immediately settle into a clean, profitable structure. For more than two years after the June 2020 deal, DocsApp and MediBuddy operated as separate consumer-facing brands under the same parent company, an arrangement that blurred marketing spend and brand identity without visibly working. On 6 December 2022, MediBuddy announced it would shut DocsApp down entirely and migrate its subscribers onto the MediBuddy app, ending the two-brand structure for good, Business2Business reported at the time. The report tied the decision explicitly to the broader 2022 “funding winter” then squeezing Indian startups into restructuring, rather than to any single product failure.

The financial numbers from those years explain the pressure. In FY22, MediBuddy’s operating revenue grew a strong 58.5% to ₹234.1 crore, but its net loss still widened to ₹259.3 crore, largely because advertising and promotion spend jumped roughly 6.8 times to ₹119.5 crore, driven by signing Amitabh Bachchan as brand ambassador, Entrackr reported in December 2022. The following year was worse on the bottom line even as the top line kept growing: FY23 revenue rose 27.2% to ₹297.7 crore, but net loss grew 24% to ₹321.7 crore, with employee costs alone surging 90% to ₹135.1 crore, Inc42 reported on 11 December 2023. Two consecutive years of accelerating losses, one high-profile celebrity marketing bet that did not visibly move the loss line in the right direction, and a public brand shutdown inside the same eighteen-month window make this the company’s genuine near-death stretch, even though it never ran out of cash outright.

The turning point

The turn came from acquisition, not advertising. On 9 February 2023, MediBuddy acquired vHealth by Aetna, the India business of US-based Aetna Inc, a CVS Health company, picking up a subscription-based, business-to-business primary healthcare operation with about 1.4 million subscribers at the time, Inc42 and PR Newswire reported. Inc42’s coverage at the time of the deal estimated vHealth would contribute roughly 30% of MediBuddy’s topline in FY24. The following fiscal year bore that out at a larger scale than the estimate implied: operating revenue jumped from ₹297.7 crore in FY23 to ₹645.4 crore in FY24, a rise of more than 116%, while net loss fell from ₹321.7 crore to ₹215.7 crore in the same period, per Entrackr’s FY25 report, which included the FY24 comparison figures. A single corporate-health-book acquisition, absorbed into the existing platform, did more in one year to both grow revenue and shrink losses than the previous two years of organic growth and consumer marketing combined.

The money behind it

MediBuddy’s capital history runs in distinct phases. The June 2020 DocsApp-MediBuddy merger came bundled with $20 million in fresh funding for the joint entity, Entrackr reported at the time. Less than a year later, in a tranche disclosed in March 2021, the company’s valuation crossed $164-167 million (₹1,190-1,210 crore) on a $13.2 million Series E allocation, with India Life Sciences Fund as lead investor alongside ALES Global Investment Partnership and existing backers including Bessemer India, Rebright Partners and TEAMFund, Entrackr reported on 25 March 2021.

The largest single round came in February 2022: a $125 million Series C led by Quadria Capital and Lightrock India, reported by Business Standard, though the outlet’s contemporaneous coverage said the company did not disclose a valuation for that round. A 2025 Samena Capital market note, discussing MediBuddy’s later pre-IPO plans, referred back to that round as having valued the company at $400 million — a figure this piece could not independently confirm against a second primary source, so it is presented here only as reported. In August 2023, existing investors Quadria Capital, Lightrock and TEAMFund added another $18 million earmarked for acquisitions, with CEO Satish Kannan citing a 95.5% compound annual growth rate over the prior three years, Digital Health News reported. Entrackr’s December 2025 report on FY25 financials put total funding raised at over $190 million to date.

By mid-2025, MediBuddy was working with Avendus Capital on a pre-IPO round originally targeted at $130 million, later scaled back to around $60 million, split roughly between $25-30 million of primary capital and $30-35 million of secondary shares to give early angel investors an exit, according to the Samena Capital note. No confirmed valuation for that round could be verified from a source this piece could open directly, so it has been left out rather than repeated from unverified aggregator figures.

How it makes money

MediBuddy earns in three overlapping ways. The first is fee-for-service: a consumer pays per teleconsultation, per lab test, or for a home health checkup package, and MediBuddy keeps a margin on top of what it pays the doctor, lab partner or courier. The second is retail pharmacy: MediBuddy takes orders for prescription medicines and earns a trading margin on the medicines it delivers, the same model as any e-pharmacy, which is why “cost of materials consumed” — effectively the wholesale cost of medicines and diagnostic consumables — is consistently the single largest expense line in its filings. The third, and the one that changed the company’s trajectory most, is the corporate channel inherited largely through the vHealth acquisition: employers pay MediBuddy a subscription, priced per employee, to give staff and their dependents access to the doctor network, health checks and a managed panel of hospitals, billed to the company rather than the individual.

The part people tend to get wrong is assuming MediBuddy is primarily a consumer telehealth app competing purely on app downloads and doctor-call volumes. Its more durable revenue increasingly sits in negotiated, renewable contracts with employers rather than one-off consumer transactions, which is a fundamentally different sales motion — enterprise HR and benefits teams, not consumer marketing — even though the company still spends heavily on consumer brand campaigns, as the FY22 advertising spike showed. MediBuddy has also sold a “MediBuddy Gold” subscription directly to consumers, offering discounted or unlimited consultations for a periodic fee, extending the same subscription logic to the retail side, per the company’s own business-model materials reviewed for this piece.

The numbers

MediBuddy’s own restated figures, disclosed across successive annual filings and reported each year by Entrackr and Inc42, show revenue growth that has consistently outpaced the shrinkage in losses until the most recent two years, when losses finally began narrowing in absolute terms.

FY25’s total income, including non-operating income, came to ₹743 crore, against total expenses of ₹879 crore, roughly flat versus FY24, Entrackr reported in December 2025. Within that expense base, cost of materials consumed was ₹333 crore (38% of total expenses), employee benefit costs were ₹176.8 crore (up 8% year-on-year, including about ₹6 crore of ESOP charges), and sales payouts and commissions were ₹155.47 crore, down 7% from the year before. MediBuddy’s EBITDA loss narrowed to ₹103 crore in FY25, taking its EBITDA margin to -14.19% from -25.67% in FY24. On a unit-economics basis, the company spent ₹1.21 to earn every ₹1 of operating revenue in FY25 — down from ₹2.08 in FY22, according to Entrackr’s respective reports for those years, a meaningful three-year improvement in capital efficiency even though the business remains loss-making. As of March 2025, MediBuddy held current assets of ₹395.2 crore, of which only ₹80 crore was cash and bank balance, against a net loss for the year of ₹137 crore.

Where the money comes from

MediBuddy does not publish an exact percentage split of revenue between its corporate and consumer channels in the filings reviewed for this piece, so that specific number is left out rather than estimated. What the company does state publicly is scale on the corporate side: it says its health benefit programmes now reach more than 1,000 organisations, including Fortune 500 companies, covering more than 5 million employees and their dependents, according to MediBuddy’s own corporate-offering materials. The scale jump is traceable directly to the vHealth acquisition, which alone brought roughly 1.4 million subscribers into MediBuddy’s base and was expected to supply close to 30% of FY24 revenue on its own, per Inc42’s February 2023 report on the deal — a single acquisition changing the geography of MediBuddy’s revenue book more than several years of organic consumer growth had managed. The surprise, given how consumer-facing MediBuddy’s marketing has been, is how much of its recent growth is really an enterprise sales story wearing a consumer app’s interface.

The risks

Three risks stand out from MediBuddy’s own disclosed numbers rather than from speculation about the business. First, the company’s cash buffer is thin against its burn: FY25 closed with only ₹80 crore in cash and bank balance against a net loss of ₹137 crore and an EBITDA loss of ₹103 crore for the year, meaning continued external funding, not internally generated cash, is what keeps the model running, a dependence visible in the pre-IPO round’s built-in secondary component to give early investors a way out rather than waiting for a listing. Second, the largest single cost line, cost of materials consumed at ₹333 crore or 38% of FY25 expenses, sits in medicine and diagnostic-consumable distribution, a thin-margin, logistics-heavy segment where MediBuddy competes directly with dedicated e-pharmacy and diagnostics players on price, leaving limited room to raise margins without losing volume. Third, the corporate health-benefits channel that now drives much of MediBuddy’s growth depends on renewable contracts with HR and benefits teams at large employers; those budgets can be cut or re-tendered in a downturn, and MediBuddy competes for the same corporate wallet against rivals such as Practo, Plum and other benefits platforms, making customer concentration and contract renewal a structural risk rather than a hypothetical one.

The takeaway

The most transferable lesson from MediBuddy’s numbers is not about telehealth specifically — it is about what actually moves a loss-making subscription business toward breakeven. MediBuddy spent heavily and visibly on consumer brand marketing in FY22, and its losses got worse, not better, in the year that spend peaked. What changed the trajectory was buying an existing, contracted revenue base — vHealth’s roughly 1.4 million B2B subscribers — and running it through MediBuddy’s existing cost structure, which delivered more revenue growth and more loss reduction in a single year than two years of advertising and organic growth combined. For a founder or operator watching a growth curve that will not bend, the MediBuddy case is a concrete argument for buying distribution with an existing, already-paying customer base over spending further to acquire the same customers one at a time.

Frequently asked questions

What does MediBuddy do?

MediBuddy runs a digital healthcare platform offering teleconsultations, medicine delivery, diagnostics and lab tests, and health checkups to consumers, alongside corporate health benefit programmes it sells to employers for their staff and dependents.

Who founded MediBuddy and when?

MediBuddy’s current form traces to DocsApp, founded in 2015 by IIT Madras alumni Satish Kannan and Enbasekar Dinadayalane, which merged with the existing MediBuddy platform in June 2020 and fully absorbed the DocsApp brand by December 2022.

Is MediBuddy profitable?

No. MediBuddy reported a net loss of ₹137 crore in FY25 on operating revenue of ₹724.6 crore, though that loss was 37% narrower than FY24’s ₹215.7 crore loss, per Entrackr’s December 2025 report.

How much has MediBuddy raised and what is it worth?

MediBuddy has raised more than $190 million to date, per Entrackr, across rounds including a $125 million Series C in February 2022 and an $18 million extension in August 2023. Its valuation crossed $165 million in March 2021 (Entrackr); a later figure of $400 million tied to the 2022 round appears in a single 2025 market note and could not be independently confirmed for this piece.

Is MediBuddy going to IPO?

MediBuddy was working with Avendus Capital in 2025 on a pre-IPO fundraise, initially sized at $130 million and later scaled to around $60 million with a secondary component for early investor exits, a step companies typically take ahead of, not instead of, a future listing; no IPO date has been confirmed in the sources reviewed for this piece.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Entrackr, December 2025 — “Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%”
• Inc42, 11 December 2023 — “MediBuddy’s FY23 Loss Jumps 24% To INR 321.7 Cr As Business Grows”
• Entrackr, 19 December 2022 — “MediBuddy’s revenue grows 58% in FY22, losses near Rs 250 Cr”
• Entrackr, 25 March 2021 — “MediBuddy’s valuation crosses $165 Mn in latest funding tranche”
• Entrackr, 4 June 2020 — “DocsApp merges with MediBuddy, scores $20 Mn funding for the joint entity”
• Business2Business.co.in, 2022 — “DocsApp shuts down, merges with parent MediBuddy”
• Inc42, February 2023 — “Healthtech Startup MediBuddy Acquires Indian Business Of US-Based Aetna”
• PR Newswire, 9 February 2023 — “MediBuddy acquires ‘vHealth by Aetna’, the India health business of Aetna Inc., a CVS Health company”
• Digital Health News, August 2023 — “MediBuddy Secures $18 Mn Funding from Quadria, Lightrock, & TEAMFund to Drive Acquisitions”
• Business Standard, 22 February 2022 — “Online healthcare firm MediBuddy raises $125 mn in Series-C funding”
• Samena Capital, June 2025 — “Grapevine: Jupiter, Medibuddy, Scaler, Bloom Hotels In Fundraising News”
• Business2Business.co.in, June 2020 — reporting on the DocsApp-MediBuddy merger structure
• Vizologi, business model canvas reference, accessed September 2026 — MediBuddy revenue-stream and MediBuddy Gold subscription description

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.